Dan Kuritzkes Dr. Kuritzkes is chairman of the HIV Medicine Association and a member of the HIV Advisory Board of the medical education and communications company, Clinical Care Options. For the federal government he serves as Vice-Chair of the Executive Committee of the NIAID sponsored AIDS Clinical Trials Group and Chair of that groups Scientific Agenda Steering Committee. According to the group's by-laws, "the Scientific Agenda Steering Committee oversees and coordinates the ACTG's research priorities, scientific agenda through the Research Agenda Committees, and patient and laboratory resources." Disclosures made for "The New York Course" (2008) via the Medscape.com site Daniel R. Kuritzkes, MD, has served as a consultant to: Abbott Avexa Boehringer Ingelheim Bristol-Myers Squibb Gilead GlaxoSmithKline Human Genome Sciences Merck Monogram Biosciences Panacos Pfizer Roche Schering-Plough Siemens Tibotec Johnson & Johnson Trimeris VIRxSYS Dr. Kuritzkes has received honoraria from: Abbott Avexa Boehringer Ingelheim Bristol-Myers Squibb Gilead GlaxoSmithKline Human Genome Sciences Merck Monogram Biosciences Panacos Pfizer Roche Schering-Plough Siemens VIRxSYS Dr. Kuritzkes has received grant support from: Boehringer Ingelheim Gilead Human Genome Sciences Merck Roche Schering-Plough Trimeris (To his credit, he appears not to do speakers bureaus. Nor does he own stock or stock options in companies whose products he tests, evaluates and/or promotes.) Disclosures made for XIV Conference on Retroviruses and Opportunistic Infections (CROI), February 2007: (from session 30: "New ARV Agents, Resistance Mechanisms, and Clinical Resistance") Bayer Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline (from session 34: "Emerging Strategies for the Treatment of HIV") Human Genome Sciences (has a monoclonal antibody against CCR5 in development; also makes treatment for hepatitis C) Monogram Biosciences Pfizer Roche-Trimeris Schering-Plough Financial disclosures from the Clinical Care Options website, where Dr. Kuritzkes serves on the group's HIV Advisory Board (and is paid to write summaries for the medical communications service): Daniel R. Kuritzkes, MD Director of AIDS Research Brigham & Women's Hospital Professor of Medicine Harvard Medical School Partners AIDS Research Center Boston, Massachusetts Paid consultant for: Abbott Laboratories Anormed (recently acquired by Genzyme Corp.) Avexa Bayer Diagnostics (recently purchased by Siemens Medical Solutions) Boehringer Ingelheim Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline Merck Monogram Biosciences Panacos Pfizer Roche-Trimeris Schering-Plough Tanox Tibotec VIRxSYS Speaking fees from: Abbott Laboratories Avexa Bayer Boehringer Ingelheim Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline Human Genome Sciences Merck Monogram Biosciences Panacos Pfizer Roche-Trimeris VIRxSYS Research support from: Bayer Boehringer Ingelheim Human Genome Sciences Merck Schering-Plough Tibotec In a 2005 interview on the Medscape.com site, Dr. Kuritzkes volunteered the following disclosures: Daniel R. Kuritzkes, MD, has disclosed that he has received grant/research support from and has served as a consultant and/or on the advisory boards for: Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline Schering-Plough Ortho Biotech He has also disclosed that he has served as a paid consultant for: Abbott Laboratories Gilead Sciences Pfizer Roche-Trimeris Roche Molecular Diagnostics ViroLogic (now Monogram Biosciences) Daniel R Kuritzkes 2004 IAS disclosures: Abbott: Consultant/Advisor, Member of Speaker’s Bureau Bayer: Consultant/Advisor Boehringer Ingelheim: Consultant/Advisor Bristol-Myers Squibb: Consultant/Advisor, Member of Speaker’s Bureau Gilead: Consultant/Advisor, Member of Speaker’s Bureau GlaxoSmithKline: Consultant/Advisor, Member of Speaker’s Bureau Ortho Biotech: Consultant/Advisor, Member of Speaker’s Bureau Pfizer: Consultant/Advisor, Member of Speaker’s Bureau Roche: Consultant/Advisor, Member of Speaker’s Bureau ViroLogic (now Monogram Biosciences): Consultant/Advisor, Member of Speaker’s Bureau Kuritzkes 2004 clinicaloptions.com (and imedoptions.com) disclosures Dr. Kuritzkes has served as a paid consultant for or received speaking fees from: Abbott Bayer Boehringer Ingelheim Bristol-Myers Squibb Gilead GlaxoSmithKline Merck Pfizer Roche Schering-Plough Shire Tanox Ortho Biotech ViroLogic Dr. Kuritzkes has received grants or research support from: Boehringer Ingelheim Bristol-Myers Squib GlaxoSmithKline Tanox Source: CME program, “Investigational Protease Inhibitor: Role of Tipranavir,” at imedoptions.com (URL: http://www.clinicaloptions.com/hiv/treatment/switching/ Accessed 03-01-05) Kuritzkes 2005 clinicaloptions.com (and imedoptions.com) disclosures Daniel R. Kuritzkes has served as a paid consultant for: Abbott Laboratories Bayer Boehringer Ingelheim Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline OrthoBiotech Panacos Pfizer Roche Pharmaceuticals Schering-Plough Tanox ViroLogic Dr. Kuritzkes has received speaking fees from: Abbott Laboratories Bayer Boehringer Ingelheim Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline Roche Pharmaceuticals ViroLogic Dr. Kuritzkes has received grants or research support from: Boehringer Ingelheim Bristol-Myers Squibb GlaxoSmithKline Human Genome Sciences OrthoBiotech Schering-Plough Tanox Kuritzkes 2002 financial disclosures Dr. Kuritzkes has served as a paid consultant to: Abbott Bristol-Myers Squibb Chiron Gilead GlaxoSmithKline Roche Triangle Trimeris Virco ViroLogic Dr. Kuritzkes has received speaking fees from: Abbott Bristol-Myers Squibb Gilead GlaxoSmithKline Roche ViroLogic Dr. Kuritzkes has received grant support from: Agouron Bristol-Myers Squibb GlaxoSmithKline Roche Tanox Triangle Trimeris Visible Genetics Source: Kuritzkes DR. “Perspective: Managing Treatment Failure.” Topics in HIV Medicine, March/April 2002; Volume 10, Issue 1.